Cartilage oligomeric matrix protein, C-terminal cross-linking telopeptide of type II collagen, and matrix metalloproteinase-3 as biomarkers for knee and hip osteoarthritis (OA) diagnosis: a systematic review and meta-analysis

被引:76
作者
Hao, H. Q. [2 ]
Zhang, J. F. [1 ,3 ]
He, Q. Q. [1 ]
Wang, Z. [2 ]
机构
[1] Shanxi Med Univ, Sch Management, Taiyuan 030001, Shanxi, Peoples R China
[2] Shanxi Univ Chinese Med, Sch Basic Med, Taiyuan 030001, Shanxi, Peoples R China
[3] Shanxi Med Hlth Media Grp Co Ltd, Taiyuan 030001, Shanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Osteoarthritis; COMP; CTX-II; MMP-3; Biomarker; URINARY CTX-II; SYNOVIAL-FLUID; SERUM-LEVELS; RADIOGRAPHIC HIP; GENERALIZED OSTEOARTHRITIS; DISEASE PROGRESSION; TISSUE INHIBITOR; COMP; ARTHRITIS; JOINT;
D O I
10.1016/j.joca.2018.10.009
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objective: This study was design to examine the diagnostic performance of cartilage oligomeric matrix protein (COMP), C-terminal cross-linking telopeptide of type II collagen (CTX-II), and matrix metalloproteinase-3 (MMP-3) as biomarker for knee and hip OA. Methods: Systematic search on multiple databases was completed in January 2018 using certain keywords. COMP, CTX-II, MMP-3 levels in knee and hip OA patients and healthy individuals were collected and calculated. Differences between subgroups were expressed as standardized mean differences (SMD). Subgroup analyses were performed to compare COMP, CTX-II, and MMP-3 performance between measuring sources, genders, large and small sample size and diagnostic criteria for OA patients. Results: A moderate performance of COMP in distinguishing between knee (SMD: 0.68; 95% confidence intervals (CI): 0.43-0.93; P < 0.0001) or hip (SMD: 0.25; 95% CI, 0.10, 0.40; P = 0.0008) OA patients and controls were found. CTX-II showed a moderated standardised mean differences (SMD) of 0.48 (95% CI, 0.32, 0.64; P < 0.0001) in the detection of knee OA and a large SMD of 0.76 (95% CI, 0.09, 1.42; P = 0.03) in diagnosing hip OA. A small SMD of 0.32 (95% CI, -0.03, 0.67; P = 0.07) was found for MMP-3 performance and the results did not reach statistic significance. Progression study revealed potential effectiveness of serum COMP in predicting OA progression. Subgroup analysis showed that serum COMP and urinary CTX-II performed better in male than female. Study size and diagnostic criteria did not significantly influence the pooled SMD, but they might be the sources of heterogeneity among studies. Conclusion: The overall results indicates that serum COMP and urinary CTX-II can distinguish between knee or hip OA patients and control subjects. Serum COMP is effective in predicting OA progression. Further researches with rigorous study design and a larger sample size are required to validate our findings. (C) 2018 Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
引用
收藏
页码:726 / 736
页数:11
相关论文
共 81 条
[61]  
Ok SM, 2017, CRANIO J CRANIOMANDI, V1
[62]   Serum levels of matrix metalloproteinase-3 in relation to the development of radiological damage in patients with early rheumatoid arthritis [J].
Posthumus, MD ;
Limburg, PC ;
Westra, J ;
Cats, HA ;
Stewart, RE ;
van Leeuwen, MA ;
van Rijswijk, MH .
RHEUMATOLOGY, 1999, 38 (11) :1081-1087
[63]  
RegoPerez I, 2011, BMC MUSCOSKEL DISORD, V12, P264
[64]   Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment [J].
Ribbens, C ;
Porras, MMY ;
Franchimont, N ;
Kaiser, MJ ;
Jaspar, JM ;
Damas, P ;
Houssiau, FA ;
Malaise, MG .
ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (02) :161-166
[65]   Interpretation of random effects meta-analyses [J].
Riley, Richard D. ;
Higgins, Julian P. T. ;
Deeks, Jonathan J. .
BMJ-BRITISH MEDICAL JOURNAL, 2011, 342 :964-967
[66]   Relationship between CTX-II and patient characteristics, patient-reported outcome, muscle strength, and rehabilitation in patients with a focal cartilage lesion of the knee: a prospective exploratory cohort study of 48 patients [J].
Rotterud, Jan Harald ;
Reinholt, Finn P. ;
Beckstrom, Karen Johanne ;
Risberg, May Arna ;
Aroen, Asbjorn .
BMC MUSCULOSKELETAL DISORDERS, 2014, 15
[67]  
SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583
[68]   Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein [J].
Senolt, L ;
Braun, M ;
Olejárová, M ;
Forejtová, S ;
Gatterová, J ;
Pavelka, K .
ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (06) :886-890
[69]  
Seny DD, 2015, PLOS ONE, V10
[70]   Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years [J].
Sharif, M ;
Kirwan, JR ;
Elson, CJ ;
Granell, R ;
Clarke, S .
ARTHRITIS AND RHEUMATISM, 2004, 50 (08) :2479-2488